SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
06 2021
Historique:
received: 14 01 2021
revised: 19 02 2021
accepted: 23 02 2021
pubmed: 20 3 2021
medline: 8 6 2021
entrez: 19 3 2021
Statut: ppublish

Résumé

Little is known about the risk of SARS-CoV-2 infection and transmission in educational settings. Public Health England initiated a study, COVID-19 Surveillance in School KIDs (sKIDs), in primary schools when they partially reopened from June 1, 2020, after the first national lockdown in England to estimate the incidence of symptomatic and asymptomatic SARS-CoV-2 infection, seroprevalence, and seroconversion in staff and students. sKIDs, an active, prospective, surveillance study, included two groups: the weekly swabbing group and the blood sampling group. The swabbing group underwent weekly nasal swabs for at least 4 weeks after partial school reopening during the summer half-term (June to mid-July, 2020). The blood sampling group additionally underwent blood sampling for serum SARS-CoV-2 antibodies to measure previous infection at the beginning (June 1-19, 2020) and end (July 3-23, 2020) of the summer half-term, and, after full reopening in September, 2020, and at the end of the autumn term (Nov 23-Dec 18, 2020). We tested for predictors of SARS-CoV-2 antibody positivity using logistic regression. We calculated antibody seroconversion rates for participants who were seronegative in the first round and were tested in at least two rounds. During the summer half-term, 11 966 participants (6727 students, 4628 staff, and 611 with unknown staff or student status) in 131 schools had 40 501 swabs taken. Weekly SARS-CoV-2 infection rates were 4·1 (one of 24 463; 95% CI 0·1-21·8) per 100 000 students and 12·5 (two of 16 038; 1·5-45·0) per 100 000 staff. At recruitment, in 45 schools, 91 (11·2%; 95% CI 7·9-15·1) of 816 students and 209 (15·1%; 11·9-18·9) of 1381 staff members were positive for SARS-CoV-2 antibodies, similar to local community seroprevalence. Seropositivity was not associated with school attendance during lockdown (p=0·13 for students and p=0·20 for staff) or staff contact with students (p=0·37). At the end of the summer half-term, 603 (73·9%) of 816 students and 1015 (73·5%) of 1381 staff members were still participating in the surveillance, and five (four students, one staff member) seroconverted. By December, 2020, 55 (5·1%; 95% CI 3·8-6·5) of 1085 participants who were seronegative at recruitment (in June, 2020) had seroconverted, including 19 (5·6%; 3·4-8·6) of 340 students and 36 (4·8%; 3·4-6·6) of 745 staff members (p=0·60). In England, SARS-CoV-2 infection rates were low in primary schools following their partial and full reopening in June and September, 2020. UK Department of Health and Social Care.

Sections du résumé

BACKGROUND
Little is known about the risk of SARS-CoV-2 infection and transmission in educational settings. Public Health England initiated a study, COVID-19 Surveillance in School KIDs (sKIDs), in primary schools when they partially reopened from June 1, 2020, after the first national lockdown in England to estimate the incidence of symptomatic and asymptomatic SARS-CoV-2 infection, seroprevalence, and seroconversion in staff and students.
METHODS
sKIDs, an active, prospective, surveillance study, included two groups: the weekly swabbing group and the blood sampling group. The swabbing group underwent weekly nasal swabs for at least 4 weeks after partial school reopening during the summer half-term (June to mid-July, 2020). The blood sampling group additionally underwent blood sampling for serum SARS-CoV-2 antibodies to measure previous infection at the beginning (June 1-19, 2020) and end (July 3-23, 2020) of the summer half-term, and, after full reopening in September, 2020, and at the end of the autumn term (Nov 23-Dec 18, 2020). We tested for predictors of SARS-CoV-2 antibody positivity using logistic regression. We calculated antibody seroconversion rates for participants who were seronegative in the first round and were tested in at least two rounds.
FINDINGS
During the summer half-term, 11 966 participants (6727 students, 4628 staff, and 611 with unknown staff or student status) in 131 schools had 40 501 swabs taken. Weekly SARS-CoV-2 infection rates were 4·1 (one of 24 463; 95% CI 0·1-21·8) per 100 000 students and 12·5 (two of 16 038; 1·5-45·0) per 100 000 staff. At recruitment, in 45 schools, 91 (11·2%; 95% CI 7·9-15·1) of 816 students and 209 (15·1%; 11·9-18·9) of 1381 staff members were positive for SARS-CoV-2 antibodies, similar to local community seroprevalence. Seropositivity was not associated with school attendance during lockdown (p=0·13 for students and p=0·20 for staff) or staff contact with students (p=0·37). At the end of the summer half-term, 603 (73·9%) of 816 students and 1015 (73·5%) of 1381 staff members were still participating in the surveillance, and five (four students, one staff member) seroconverted. By December, 2020, 55 (5·1%; 95% CI 3·8-6·5) of 1085 participants who were seronegative at recruitment (in June, 2020) had seroconverted, including 19 (5·6%; 3·4-8·6) of 340 students and 36 (4·8%; 3·4-6·6) of 745 staff members (p=0·60).
INTERPRETATION
In England, SARS-CoV-2 infection rates were low in primary schools following their partial and full reopening in June and September, 2020.
FUNDING
UK Department of Health and Social Care.

Identifiants

pubmed: 33740430
pii: S2352-4642(21)00061-4
doi: 10.1016/S2352-4642(21)00061-4
pmc: PMC9764982
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

417-427

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
Lancet Child Adolesc Health. 2020 May;4(5):397-404
pubmed: 32272089
Arch Dis Child. 2020 Jul;105(7):613-615
pubmed: 32381519
Nat Commun. 2021 Feb 10;12(1):905
pubmed: 33568663
N Engl J Med. 2020 Sep 3;383(10):981-985
pubmed: 32726550
EClinicalMedicine. 2020 Jun 03;23:100404
pubmed: 32632416
Arch Dis Child. 2020 Jul;105(7):618-619
pubmed: 32371442
China CDC Wkly. 2020 Jun 19;2(25):453-457
pubmed: 34594677
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
EClinicalMedicine. 2020 Nov;28:100597
pubmed: 33173854
Arch Dis Child. 2020 Dec;105(12):1180-1185
pubmed: 32796006
J Infect. 2020 Dec;81(6):979-997
pubmed: 32858069
Arch Dis Child. 2021 Feb;106(2):111-113
pubmed: 32747375
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
PLoS One. 2014 May 15;9(5):e97297
pubmed: 24830407
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Lancet Infect Dis. 2009 Aug;9(8):473-81
pubmed: 19628172
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
EClinicalMedicine. 2020 Sep;26:100533
pubmed: 32923993

Auteurs

Shamez N Ladhani (SN)

National Infection Service, Public Health England, London, UK; Paediatric Infectious Diseases Research Group, St George's University of London, London, UK. Electronic address: shamez.ladhani@phe.gov.uk.

Frances Baawuah (F)

National Infection Service, Public Health England, London, UK.

Joanne Beckmann (J)

East London NHS Foundation Trust, London, UK.

Ifeanichukwu O Okike (IO)

National Infection Service, Public Health England, London, UK; University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.

Shazaad Ahmad (S)

Manchester University NHS Foundation Trust, Manchester, UK.

Joanna Garstang (J)

Birmingham Community Healthcare NHS Trust, Birmingham, UK.

Andrew J Brent (AJ)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Bernadette Brent (B)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Jemma Walker (J)

National Infection Service, Public Health England, London, UK.

Nick Andrews (N)

National Infection Service, Public Health England, London, UK.

Georgina Ireland (G)

National Infection Service, Public Health England, London, UK.

Felicity Aiano (F)

National Infection Service, Public Health England, London, UK.

Zahin Amin-Chowdhury (Z)

National Infection Service, Public Health England, London, UK.

Louise Letley (L)

National Infection Service, Public Health England, London, UK.

Jessica Flood (J)

National Infection Service, Public Health England, London, UK.

Samuel E I Jones (SEI)

National Infection Service, Public Health England, London, UK.

Ray Borrow (R)

Public Health England, Manchester Royal Infirmary, Manchester, UK.

Ezra Linley (E)

Public Health England, Manchester Royal Infirmary, Manchester, UK.

Maria Zambon (M)

National Infection Service, Public Health England, London, UK.

John Poh (J)

National Infection Service, Public Health England, London, UK.

Vanessa Saliba (V)

National Infection Service, Public Health England, London, UK.

Gayatri Amirthalingam (G)

National Infection Service, Public Health England, London, UK.

Jamie Lopez Bernal (J)

National Infection Service, Public Health England, London, UK.

Kevin E Brown (KE)

National Infection Service, Public Health England, London, UK.

Mary E Ramsay (ME)

National Infection Service, Public Health England, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH